Pharmacological research and clinical applications progress of Lianhua Qingwen capsules/granules in respiratory diseases
10.12092/j.issn.1009-2501.2021.10.010
- Author:
Yujie YIN
1
;
Liping CHANG
1
Author Information
1. State Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine Medicines, Key Laboratory of National Administration of Traditional Chinese Medicine (Cardiovascular & Cerebrovascular Collateral Disease), Hebei Institute of Integrated TCM and Western Medicine
- Publication Type:Journal Article
- Keywords:
COVID-19;
Influenza;
Lianhua Qingwen;
Pneumonia;
Respiratory diseases;
Traditional Chinese medicine
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(10):1174-1180
- CountryChina
- Language:Chinese
-
Abstract:
Lianhua Qingwen capsules/granules is an innovative Chinese medicine developed under the guidance of the TCM collateral disease theory. It has the efficacy of "clearing heat and removing toxin, ventilating the lungs and discharging heat". In 2003, it was approved as a new drug by the China National Medical Products Administration, through expedited approval during/SARS, and now, it has become a representative proprietary Chinese medicine for the treatment of infectious diseases of the respiratory system. Pharmacodynamic studies have revealed that LianhuaQingwen has broad-spectrum antiviral, antibacterial and anti-inflammatory, antipyretic, cough-relieving and immunoregulation effects. Clinically it has been used in the treatment of communicable and infectious respiratory diseases such as COVID-19, influenza, upper respiratory infection, pulmonary infections, acute exacerbation of chronic obstructive pulmonary disease, etc. and has achieved remarkable curative effects.
